Agios Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Good morning. And thanks so much for joining us on day 2 of Oppenheimer's 31st Annual Healthcare Conference. My name is Mark Breidenbach. I'm part of the Oppenheimer's biotech equity research team. And this morning, I'm pleased to be hosting a fireside chat with Agios, which is developing novel therapies for rare diseases.
We're joined today by the company's CEO, Jackie Fouse. And we might be joined in a little bit by CMO, Chris Bowden. We'll be sure to leave a few minutes at the end for Q&A. So I would encourage anyone in the audience who has a question to make use of the question box at the bottom of the -- of your video. So thanks everyone for joining in today. And let's go ahead and get started.
Questions & Answers
Jackie, I think it's fair to say, Agios stands out as one of the biggest pivot stories in biotech in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |